ANI Pharmaceuticals, Inc. · NASDAQ:ANIP
ANI Pharmaceuticals — Q3 2026 Earnings Presentation
39 slides from ANI Pharmaceuticals's earnings presentation, Nov 5, 2026
Slide 1: Q3 2026 Earnings Results & Offer to Acquire Egetis Therapeutics
Q3 2026 Earnings Results & Offer to Acquire Egetis Therapeutics November 5, 2026 © 2026 ANI Pharmaceuticals, Inc. 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that are not historical facts, including statements about o
Slide 3: Presentation of financial information
Presentation of financial information Non-GAAP Financial Measures Adjusted non-GAAP EBITDA ANI’s management considers adjusted non-GAAP EBITDA to be an important financial indicator of ANI’s operating performance, providing investors and analysts with a useful measure of operating results unaffected
Slide 4: Egetis Therapeutics offer
Egetis Therapeutics offer This presentation includes discussion of our public offer for the shares, the convertible loan 2023:1 (the “Convertible”) and the warrants 2023/2033:1 (the “Warrants”) of Egetis, a Swedish public limited liability company (the “Offer”), which is subject to Swedish disclosur
Slide 5: Agenda
Agenda 1 Opening Remarks – Nikhil Lalwani, CEO • ANI’s Strategy • Recent Business Highlights • Egetis Offer Overview 2 MCT8 Deficiency & EMCITATE Overview – Mary Pao, M.D., Ph.D., CMO Nikhil Lalwani Mary Pao, M.D., Ph.D. 3 Rare Disease Commercial Update – Chris Mutz, Head of Rare Disease CEO CMO • E
Slide 6: Opening Remarks
Opening Remarks Nikhil Lalwani CH I E F E X E CU TI V E O F F I CE R © 2026 ANI Pharmaceuticals, Inc. 6
Slide 7: 2026 strategic priorities to drive long-term growth
2026 strategic priorities to drive long-term growth R E D I S E AS E RA Accelerate Continued excellence Execute disciplined transformation in Generics R&D and capital allocation BR A into leading Rare operations strategy N Disease company DS ANI’s virtuous • Maximize Cortrophin • Leverage superior •
Slide 8: Q3 2026 highlights
Q3 2026 highlights Total Net Revenues ($M)(1) Adjusted Non-GAAP EBITDA ($M)(2) • Strong top- and bottom-line +28% growth driven by Rare Disease and Generics $290.8 +40% $83.3 • Rare Disease Q3 net revenue $227.8 $108.4 growth of 36% YoY; momentum in Cortrophin Gel $59.6 $98.7 existing specialties an
Slide 9: Executing 2026 priorities to drive long-term growth and value creation
Executing 2026 priorities to drive long-term growth and value creation Accelerating transformation to a leading rare disease company $138.7M ✓ Existing specialties: continued momentum in 3Q26 3Q26 net revenues ✓ Gout expansion: strong demand generation and increased contribution to 3Q26 Cortrophin r
Slide 10: Executing 2026 priorities to drive long-term growth and value creation
Executing 2026 priorities to drive long-term growth and value creation Continued excellence in Generics business Disciplined capital allocation strategy Investing in organic growth via dedicated Generated 3Q26 Generics revenue of organization for Cortrophin Gel in acute gouty $104.5M, up 11% YoY art
Slide 11: Offer to acquire Egetis Therapeutics advances ANI's transformation into a leading Rare Disease company
Offer to acquire Egetis Therapeutics advances ANI’s transformation into a leading Rare Disease company Expands the scope and scale of ANI’s Rare Disease business by broadening Company’s commercial footprint and adding a product with over $300M in peak sales potential in its approved indication New,
Slide 12: EMCITATE has strong fundamentals with significant growth potential
EMCITATE has strong fundamentals with significant growth potential First and only FDA-approved treatment for peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare, X-linked disorder characterized by severe CNS hypothyroidism and simultaneous peripheral thyrotoxicosis Potential to addres
Slide 13: Transaction financial terms
Transaction financial terms • Cash tender offer of SEK 11.25 per share Consideration • Total offer value of SEK $5.6B (~$560M); net enterprise value of ~$434M reflects estimated net proceeds of Egetis’ PRV monetization(1) • Funded by combination of existing ANI cash on hand and up to $300M of debt s
Slide 14: MCT8 Deficiency & EMCITATE Overview
MCT8 Deficiency & EMCITATE Overview Mary Pao, M.D., Ph.D. CH I E F M E D I CA L O F F I CE R © 2026 ANI Pharmaceuticals, Inc. 14
Slide 15: MCT8 deficiency is an ultra-rare, endocrinologic disease
MCT8 deficiency is an ultra-rare, endocrinologic disease characterized by severe CNS hypothyroidism and simultaneous peripheral thyrotoxicosis Rare, severely debilitating, life-shortening condition1 Caused by mutations in Impaired transport of TH leads the SLC16A2 gene, located to low T3 levels in t
Slide 16: With MCT8 deficiency, profound disabilities compound across systems, requiring lifelong 24-hour care
With MCT8 deficiency, profound intellectual and physical disabilities compound across systems, requiring lifelong 24-hour care Hypothyroid Symptoms (low CNS T3) Hyperthyroid Symptoms (high peripheral T3) Brain & Cognition Cardiovascular Gastrointestinal Global developmental delay (speech and cogniti
Slide 17: Mechanism of action: EMCITATE restores thyroid hormone signaling
Mechanism of action: EMCITATE restores thyroid hormone signaling without requiring the MCT8 transporter to enter the cell How EMCITATE Works 1 Restores thyroid hormone signaling in the brain 2 Reduces serum T3 levels which cause thyrotoxicosis in the body © 2026 ANI Pharmaceuticals, Inc. 17
Slide 18: Clinical data supporting EMCITATE's FDA approval
Clinical data supporting EMCITATE’s FDA approval for the treatment of peripheral thyrotoxicosis associated with MCT8 deficiency ReTRIACt (Study 1) Triac Trial I (Study 2) Randomized, double-blind, placebo-controlled withdrawal with rescue, Open-label, single-arm, 12 months, N = 45 in ITT population
Slide 19: Additional analysis from three sources of real-world evidence
Additional analysis from three sources of real-world evidence Not included in U.S. Prescribing Information U.S. EXPANDED ACCESS EMC COHORT STUDY EMC SURVIVAL STUDY PROGRAM N = 30 N = 67 N > 600 (at time of NDA) • Real-world, retrospective cohort • Real-world, retrospective study • Effect of EMCITATE
Slide 20: Rare Disease Commercial Update
Rare Disease Commercial Update Chris Mutz H E A D O F R A R E D I SE A SE © 2026 ANI Pharmaceuticals, Inc. 20
Slide 21: Offering hope to MCT8 deficiency patients and their families
Offering hope to MCT8 deficiency patients and their families Globally, over 300 patients with MCT8 deficiency are already receiving EMCITATE through Managed Access Program, Expanded Access Program Now commercially available in the U.S. and EU © 2026 ANI Pharmaceuticals, Inc. 21
Slide 22: EMCITATE: The first and only FDA-approved therapy for MCT8 deficiency
EMCITATE: The first and only FDA-approved therapy for MCT8 deficiency AP P R O V E D B Y T H E F D A September 28, 2026 AP P R O V E D B Y T H E E U R O P E AN C O M M I S S I O N February 12, 2025 I N D I C AT I O N EMCITATE® (tiratricol) is a thyroid hormone receptor agonist indicated for the trea
Slide 23: Initial patient identification concentrated at 17 sites
Initial patient identification concentrated at 17 sites provide strong foundation for U.S. launch 17 sites where EAP patients are concentrated 1,000+ Estimated prevalent U.S. population Validated patients today 100+ Unique, actively managed patients, with confirmed mutation, including responsible cl
Slide 24: Combined Egetis and ANI capabilities to drive successful launch
Combined Egetis and ANI capabilities to drive successful launch Commercial Launch Priorities Experienced commercial and Rare Disease team with extensive • Secure payer coverage while medical affairs team hired and expertise in orphan indications providing access through onboarded PANTHERx support pr
Slide 25: Overall ACTH market growth driven by continued expansion into key indications
Overall ACTH market growth driven by continued expansion into key indications ACTH MARKET SALES Acthar Gel Purified Cortrophin® Gel • Expect continued strong multi-year growth YoY Growth -6% -4% +27% +50% +28% potential driven by large market opportunity as key indications remain $1.3B significantly
Slide 26: Cortrophin Gel has strong multi-year growth potential across indications
Cortrophin Gel has strong multi-year growth potential with addressable patient populations across indications significantly under-penetrated Acute Multiple Sclerosis Rheumatoid Nephrotic Sarcoidosis Syndrome Gout Flares Flares Arthritis (proteinuria reduction) Diagnosed ~9,900,0001 Diagnosed ~750,00
Slide 27: Cortrophin Gel 3Q26 performance
Cortrophin Gel 3Q26 performance Momentum in existing Strong demand generation in gout expansion specialties • Strong demand across existing specialties – neurology, nephrology, rheumatology, 40% +67% 2x of prescribers initiated 2+ growth in new prescriber new patient cases ophthalmology and cases ba
Slide 28: Returning ILUVIEN to growth across global markets
Returning ILUVIEN to growth across global markets New data support growth in NIU-PS indication with a focus on retina specialists SYNCHRONICITY 24-month results in chronic NIU-PS presented at American Academy of Ophthalmology in October 20261 Trial met both co-primary endpoints of mean change from I
Slide 29: Financial Overview
Financial Overview Stephen Carey CH I E F F I N A N CIAL O F F I CE R © 2026 ANI Pharmaceuticals, Inc. 29
Slide 30: 3Q 2026 Revenues
3Q 2026 Revenues Metric 3Q26 %YoY Change ($ millions) Cortrophin Gel $138.7 36% ILUVIEN(1) $22.3 34% Brands $10.0 (7%) Brand royalties and other revenue $11.5 N/A Generics and other $108.4 10% Total net revenues $290.8 28% © 2026 ANI Pharmaceuticals, Inc. 1. NIU-PS indication was merged into the ILU
Slide 31: 3Q 2026 Financial Results
3Q 2026 Financial Results Metric1 3Q26 %YoY Change ($ millions, except EPS) Total net revenues $290.8 28% Non-GAAP cost of sales $111.0 20% Non-GAAP gross margin (%) 61.8% 260 bps Non-GAAP total operating expenses $96.5 28% Adjusted Non-GAAP EBITDA $83.3 40% Adjusted Non-GAAP EPS ($) $2.70 32% • $42
Slide 32: 2026 Financial Guidance
2026 Financial Guidance Reflects significant top- and bottom-line growth Metric Current Prior YoY Growth ($ millions, except EPS) 2026 Guidance 2026 Guidance Net Revenue (Total Company) $1,085 - $1,125 $1,080 - $1,140 23 - 27% Cortrophin Gel Net Revenue $480 - $500 $520 - $540 38 - 44% ILUVIEN Net R
Slide 33: Closing Remarks
Closing Remarks Nikhil Lalwani CH I E F E X E CU TI V E O F F I CE R © 2026 ANI Pharmaceuticals, Inc. 33
Slide 34: Executing across strategic priorities to support continued growth
Executing across strategic priorities to support continued growth and transformation into a leading Rare Disease company STRATEGIC PRIORITIES 2026 OUTLOOK 2026 total 2026 adjusted non- Accelerate transformation into revenues(1) GAAP EBITDA(1)(2) leading Rare Disease company ~$1.1B ~$295M Continued e
Slide 35: Appendix
Appendix © 2026 ANI Pharmaceuticals, Inc. 35
Slide 36: Adjusted Non-GAAP EBITDA calculation and US GAAP to Non-GAAP reconciliation
Adjusted Non-GAAP EBITDA calculation and US GAAP to Non-GAAP reconciliation © 2026 ANI Pharmaceuticals, Inc. 36
Slide 37: Adjusted Non-GAAP diluted EPS calculation and reconciliation
Adjusted Non-GAAP diluted earnings per share calculation and US GAAP to Non-GAAP reconciliation 1. Adjusted non-GAAP Net Income Available to Common Shareholders excludes undistributed earnings to participating securities. 2. Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding exclude certa
Slide 38: Reconciliation of certain US GAAP to Non-GAAP financial measures
Reconciliation of certain US GAAP to Non-GAAP financial measures © 2026 ANI Pharmaceuticals, Inc. 38
Slide 39: References for Cortrophin Gel Addressable Patient Population
References for Cortrophin Gel Addressable Patient Population Gout 1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford). 2019 Dec 1;58(12):2177-2180. doi: 10.1093/rheumatology/kez196. PMID: 31168609 2. Thorpe K. Partnership to fight chronic